NHS England strikes CF treatment deal

NHS England has struck a deal with the manufacturer of three UK-licensed medicines for cystic fibrosis.

The newly available drugs are expected to benefit around 5000 potential patients. By September 2021, NICE is expected to conclude technology appraisals of the medicines. These appraisals will take into account an 18‑month data-collection period, during which NHS patients will have access to each drug in all current licensed indications; this will also apply to future extensions of the drug licenses.